Cargando…
Alitretinoin in Dermatology—An Update
Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi's sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601442/ https://www.ncbi.nlm.nih.gov/pubmed/26538721 http://dx.doi.org/10.4103/0019-5154.164426 |
_version_ | 1782394552192073728 |
---|---|
author | Bubna, Aditya Kumar |
author_facet | Bubna, Aditya Kumar |
author_sort | Bubna, Aditya Kumar |
collection | PubMed |
description | Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi's sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other retinoid responsive dermatosis that have demonstrated remission post usage of systemic alitretinoin. With a better toxicity profile, compared to the other systemic retinoids, alitretinoin could be considered a valuable treatment option in the near future for the treatment of these dermatologic disorders. |
format | Online Article Text |
id | pubmed-4601442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-46014422015-11-04 Alitretinoin in Dermatology—An Update Bubna, Aditya Kumar Indian J Dermatol E-IJD Resident's Page Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi's sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other retinoid responsive dermatosis that have demonstrated remission post usage of systemic alitretinoin. With a better toxicity profile, compared to the other systemic retinoids, alitretinoin could be considered a valuable treatment option in the near future for the treatment of these dermatologic disorders. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4601442/ /pubmed/26538721 http://dx.doi.org/10.4103/0019-5154.164426 Text en Copyright: © Indian Journal of Dermatology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | E-IJD Resident's Page Bubna, Aditya Kumar Alitretinoin in Dermatology—An Update |
title | Alitretinoin in Dermatology—An Update |
title_full | Alitretinoin in Dermatology—An Update |
title_fullStr | Alitretinoin in Dermatology—An Update |
title_full_unstemmed | Alitretinoin in Dermatology—An Update |
title_short | Alitretinoin in Dermatology—An Update |
title_sort | alitretinoin in dermatology—an update |
topic | E-IJD Resident's Page |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601442/ https://www.ncbi.nlm.nih.gov/pubmed/26538721 http://dx.doi.org/10.4103/0019-5154.164426 |
work_keys_str_mv | AT bubnaadityakumar alitretinoinindermatologyanupdate |